Rishi is a Partner at OrbiMed Advisors. In addition to Enliven, he serves or has served on the boards of Charm Therapeutics, DELFI Diagnostics, Pionyr Immunotherapeutics, Verona Pharma, Turnstone Biologics, Modis Therapeutics, NeuroPace, Avitide, Dimension Therapeutics, Symbiomix Therapeutics, ChemoCentryx, and Sientra. Rishi has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae, and ORIC Pharmaceuticals. Prior to OrbiMed, Rishi worked as a healthcare investment banker at Raymond James & Associates, a Manager of Corporate Development at Veritas Medicine, and was a summer associate at Wachtell, Lipton, Rosen & Katz.
Rishi received a J.D. from Yale Law School and an A.B. in Biochemical Sciences from Harvard College.
What is Rishi Gupta's net worth?
The estimated net worth of Rishi Gupta is at least $11.49 million as of May 16th, 2024. Mr. Gupta owns 254,814 shares of Enliven Therapeutics stock worth more than $11,492,111 as of June 20th. This net worth estimate does not reflect any other assets that Mr. Gupta may own. Learn More about Rishi Gupta's net worth.
How do I contact Rishi Gupta?
Has Rishi Gupta been buying or selling shares of Enliven Therapeutics?
Rishi Gupta has not been actively trading shares of Enliven Therapeutics during the past quarter. Most recently, Rishi Gupta sold 1,033,300 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $22.14, for a transaction totalling $22,877,262.00. Following the completion of the sale, the director now directly owns 254,814 shares of the company's stock, valued at $5,641,581.96. Learn More on Rishi Gupta's trading history.
Who are Enliven Therapeutics' active insiders?
Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Lori Kunkel (Director), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?
In the last twelve months, insiders at the sold shares 41 times. They sold a total of 437,161 shares worth more than $10,598,596.32. The most recent insider tranaction occured on June, 5th when Director Lori Anne Kunkel sold 10,000 shares worth more than $345,400.00. Insiders at Enliven Therapeutics own 3.0% of the company.
Learn More about insider trades at Enliven Therapeutics. Information on this page was last updated on 6/5/2026.
